LSA
MRNA icon

L & S Advisors’s Moderna MRNA Stock Holding History

L & S Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,214
Closed -$316K – 258
2022
Q2 		$316K Buy
2,214
+404
+22% +$57.7K 0.05% 181
2022
Q1 		$312K Sell
1,810
-737
-29% -$124K 0.04% 237
2021
Q4 		$647K Sell
2,547
-331
-12% -$96.8K 0.07% 203
2021
Q3 		$1.11M Sell
2,878
-10,081
-78% -$3.72M 0.12% 192
2021
Q2 		$3.04M Buy
12,959
+7,801
+151% +$1.39M 0.33% 93
2021
Q1 		$675K Sell
5,158
-23,169
-82% -$3.36M 0.08% 235
2020
Q4 		$2.96M Sell
28,327
-17,444
-38% -$1.76M 0.34% 97
2020
Q3 		$3.24M Buy
45,771
+8,369
+22% +$584K 0.45% 78
2020
Q2 		$2.4M Sell
37,402
-22,354
-37% -$1.22M 0.36% 81
2020
Q1 		$1.79M Buy
+59,756
New +$1.37M 0.34% 70

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

L & S Advisors's MRNA Position: Q3 2022 in Review

L & S Advisors sold out of Moderna (MRNA) in Q3 2022, closing a stake of 2,214 shares — an estimated $316K sold.

L & S Advisors first reported a position in MRNA in Q1 2020 and held it in 10 quarters. The position peaked at $3.24M in Q3 2020. 915 funds tracked by Wall St. Rank hold MRNA as of Q3 2022.

  • L & S Advisors reported no remaining Moderna position as of Q3 2022 after selling out during the quarter.
  • L & S Advisors sold 2,214 Moderna shares in Q3 2022, an estimated $316K.
  • L & S Advisors first reported a position in Moderna in Q1 2020 and held it in 10 quarters.
  • L & S Advisors's Moderna position peaked at $3.24M in Q3 2020.
  • 915 funds tracked by Wall St. Rank held Moderna as of Q3 2022.

Based on L & S Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.